Donated Livers Can Be Made Biologically Younger

Scientists Discover Perfusion Machines Can Reverse Organ Aging

A donated liver placed on ice begins dying the moment it leaves the donor's body. Surgeons have long accepted this as an immutable constraint of transplantation. New research suggests that constraint may be softer than anyone realized.

Scientists have found that livers connected to machine perfusion devices—pumps that circulate nutrients through an organ and carry away metabolic waste—appear to become biologically younger at the molecular level. The findings, shared with MIT Technology Review, offer a mechanistic explanation for something transplant surgeons have observed for years: organs from younger donors tend to perform better after transplantation, and organs that spend time on perfusion machines are less likely to fail.

The discovery represents more than a technical curiosity. If researchers can identify what makes a perfused organ biologically younger, they may be able to measure organ quality with far greater precision than current methods allow. Today, transplant teams largely rely on donor age, visual inspection, and crude biomarkers to decide whether an organ is suitable for transplantation. A molecular clock that reveals an organ's true biological state could transform those judgments.

The Molecular Science Behind Biologically Younger Organs

When an organ is removed from a donor, its cells continue consuming energy—but without blood flow to deliver oxygen and remove waste, metabolic byproducts accumulate and tissue damage accelerates. Cold storage slows this process but does not stop it. Perfusion machines, by contrast, restore something resembling normal physiology. The organ receives oxygen and nutrients; waste products are carried away.

What the researchers observed is that this restoration appears to reverse certain molecular signatures of aging. The specific markers remain an active area of investigation, but the broader field of biogerontology offers a roadmap for what scientists typically examine. Epigenetic clocks—chemical tags on DNA that change predictably with age—are among the most studied measures of biological age. Mitochondrial function is another. As cells age, their mitochondria become less efficient at producing energy and generate more damaging reactive oxygen species. Protein oxidation, which accumulates as tissues encounter metabolic stress, represents a third dimension.

Transplant surgeons and biogerontologists have increasingly argued that chronological age—the number of years a donor lived—poorly captures an organ's functional capacity. A 65-year-old donor with well-preserved mitochondria may offer a better liver than a 40-year-old donor with significant oxidative damage. The perfusion findings suggest that biological age is not merely a static property of an organ but something that can shift, at least partially, depending on the conditions the organ encounters after removal.

The implication is striking: an organ that arrives at the transplant center in a degraded state may recover some of its youth during the hours it spends on a perfusion device. The clock, in other words, may not only stop—it may run backward.

Why Younger Donor Organs Have Higher Transplant Success Rates

Transplant registries have documented for decades that organs from older donors carry higher risks of delayed function and long-term failure. Data from the Organ Procurement and Transplantation Network, which maintains the nation's transplant waiting list and outcome registry, consistently show that livers from donors over 60 have lower graft survival rates than those from donors under 40. The gap is not enormous—typically measured in percentage points over five years—but it is clinically meaningful, particularly for patients already fighting for their lives.

Several mechanisms explain this differential. Older organs have accumulated more cellular damage. Their mitochondria are less robust. Their vascular networks are stiffer and less responsive. When such an organ is subjected to the additional stress of removal, cold storage, and reperfusion, it has less reserve to draw upon.

This is precisely why perfusion machines have gained traction for marginal organs—those from older donors or donors with complicating health conditions. A liver that might have been discarded as too risky for transplantation can sometimes be rehabilitated on a perfusion device, allowing surgeons to assess its function in real time before committing to a transplant. The new research suggests that this rehabilitation may be more than functional. It may be rejuvenative.

The clinical stakes are considerable. Roughly 10,000 people in the United States are waiting for a liver transplant at any given time, according to federal data. Each year, several thousand receive one. Expanding the pool of usable organs—by making older or marginal livers more viable—could shorten waiting times and reduce deaths on the list.

Implications for the Future of Organ Transplantation

If perfusion can reliably reduce the biological age of an organ, the implications extend well beyond the operating room. Organ allocation systems currently prioritize based on a combination of donor age, recipient urgency, and geographic proximity. A validated molecular measure of organ youth could refine those algorithms, directing the healthiest organs to the sickest patients and identifying which marginal organs are worth the risk.

There is also the question of duration. Perfusion typically runs for six to 12 hours—a window that allows assessment but not indefinite preservation. If researchers can extend that window while maintaining or improving organ quality, the logistics of transplantation could change fundamentally. Organs could travel farther. Surgeries could be scheduled with greater precision. The frantic race against the clock that defines transplant logistics today could become something more measured.

The researchers behind the study hope their work will lead to new ways of testing organ health—tools that go beyond what current methods can reveal. If a simple molecular assay could tell a surgeon whether a liver is biologically 35 or biologically 60, decisions about transplantation would rest on far firmer ground.

Machine Perfusion vs. Traditional Cold Storage: A Comparison

The contrast between the two preservation methods is stark. Cold storage—flushing an organ with preservative solution, sealing it in a bag, and packing it in ice—remains the standard for most donated organs worldwide. It is inexpensive, portable, and well understood. But it buys only hours. After that, ischemic damage accumulates rapidly, and the organ becomes unsuitable for transplantation.

Perfusion machines are more complex and more costly. They require trained operators, a supply of perfusion solution, and continuous monitoring. But they extend the viable window to six to 12 hours and, according to a growing body of evidence, improve outcomes. Recent studies have suggested that organs placed on perfusion devices experience lower rates of early dysfunction after transplantation.

Adoption has grown steadily but remains far from universal. Major transplant centers in Europe and North America have invested in perfusion technology, particularly for livers and lungs. Smaller centers, constrained by budget and staffing, often continue to rely on cold storage. The new findings on biological aging may accelerate the shift—if perfusion does more than preserve, if it actually rejuvenates, the cost-benefit calculation changes.

What This Research Means for Patients on Transplant Waiting Lists

For the approximately 10,000 Americans waiting for a liver, the research offers a reason for cautious optimism—not because it will change their care tomorrow, but because it points toward a future in which more organs are usable and those organs perform better.

The path from molecular discovery to clinical practice is long. Researchers must identify which markers of biological age are most predictive of transplant success. They must validate their findings across larger populations and diverse donor characteristics. They must develop practical assays that transplant centers can run in real time. Each of these steps takes years.

But the direction of travel is clear. The field is moving toward a more nuanced understanding of what makes an organ suitable for transplantation—one that looks beyond the donor's birth date to the organ's biological state. Perfusion machines, once viewed simply as a way to buy time, may turn out to be instruments of restoration.

The clock, it seems, is not as fixed as it appeared. For patients whose lives depend on the generosity of strangers, that is a finding worth watching closely.

Source: MIT Technology Review